The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that act via steroid hormone receptors. Clinical benefit has been observed following the withdrawal of flutamide (Eulexin, Schering-Plough International), bicalutamide (Casodex, Zeneca Ltd), oestrogens, progestational agents and retinoids. For patients with progression of disease while receiving these drugs, a period of observation after withdrawal should be considered before further therapy is initiated.